Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$93.7K Buy
266
+14
+6% +$4.99K 0.02% 214
2025
Q4
$82.3K Buy
252
+44
+21% +$14K 0.02% 234
2025
Q3
$58.7K Buy
208
+24
+13% +$6.96K 0.01% 248
2025
Q2
$51.5K Buy
184
+123
+202% +$34.8K 0.01% 264
2025
Q1
$19K Buy
61
+12
+24% +$3.54K ﹤0.01% 308
2024
Q4
$12.9K Buy
49
+2
+4% +$593 ﹤0.01% 340
2024
Q3
$15.1K Sell
47
-2
-4% -$654 ﹤0.01% 301
2024
Q2
$15.2K Sell
49
-3
-6% -$881 ﹤0.01% 278
2024
Q1
$14.6K Buy
52
+6
+13% +$1.76K ﹤0.01% 323
2023
Q4
$13.3K Buy
+46
New +$12.5K ﹤0.01% 365

Other funds holding AMGN

REAP Financial Group's AMGN Position: Q1 2026 in Review

REAP Financial Group increased its Amgen (AMGN) stake by 5.6% in Q1 2026, buying an estimated $4.99K and bringing the position to 266 shares worth $93.7K. The position accounts for 0.02% of the portfolio, ranked #214.

REAP Financial Group first reported a position in AMGN in Q4 2023 and has held it in 10 quarters since. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • REAP Financial Group held 266 shares of Amgen worth $93.7K as of Q1 2026.
  • REAP Financial Group bought 14 Amgen shares in Q1 2026, an estimated $4.99K.
  • Amgen made up 0.02% of REAP Financial Group's portfolio in Q1 2026, its #214 holding.
  • REAP Financial Group first reported a position in Amgen in Q4 2023 and has held it in 10 quarters since.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on REAP Financial Group's 13F filing for Q1 2026, filed 11 May 2026.